CHMP recommends eight medicines for approval

The EMA's CHMP recommended that eight drugs be approved at its April meeting. Nine pre-approved drugs have been endorsed for new indications.


A four-day meeting in the EMA's Committee for Medicinal Products for Human Use (CHMP) has resulted in a host of recommendations on Friday.

The commission has lined up eight new drugs for approval, including Leo Pharma's tralokinumab with the commercial name Adtralza. Now, they await formal approval from the EU Commission. Ordinarily, this is seen as a formality, since the commission only goes against the EMA's suggestions on very rare occasions.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Rumored GN purchase unlikely but not impossible, say analysts

A low value assessment, a high structural value, and no dominant shareholders make GN Group a reasonable investment case for international private equity firms and industrial players. But just how likely is it? Analysts reveal their best bets for what a GN acquisition could look like.

New CFO wants to shake things up at WSA

A mere month into her new job, Marianne Wiinholt, WS Audiology’s fifth chief financial officer since the firm was established through a merger in 2019, is heralding great structural changes.

Further reading

Related articles

Latest news

See all jobs